Apolipoprotein B-containing lipoprotein (ApoB-LP) (ApoB-LP)

Apolipoprotein B-containing lipoproteins represent a class of atherogenic particles, including VLDL, IDL, and LDL, each defined by the presence of one molecule of apolipoprotein B (ApoB-100 or ApoB-48) (StatPearls, 2023). These complexes are the primary vehicles for transporting hydrophobic lipids like cholesterol and triglycerides through the plasma to meet cellular energy and structural demands (NIH, 2022). From a clinical perspective, they are the central drivers of atherosclerotic cardiovascular disease (ASCVD), as their entrapment in the arterial wall initiates the inflammatory cascade leading to plaque formation (PubMed, 2021). Therapeutic strategies targeting these lipoproteins are the cornerstone of cardiovascular risk reduction, focusing on either decreasing hepatic production or accelerating clearance from the blood. Key drug classes include statins, which inhibit cholesterol biosynthesis, and PCSK9 inhibitors, which prolong the lifespan of the LDL receptor to enhance particle uptake (Journal of Lipid Research, 2020). Monitoring ApoB levels is increasingly recognized as a more accurate biomarker of cardiovascular risk than LDL-C alone, as it reflects the total number of atherogenic particles in circulation (Circulation, 2019).

Other names

ApoB-LPsNon-HDL lipoproteinsAtherogenic lipoproteinsApoB-containing particles

Therapeutic mechanisms include the inhibition of HMG-CoA reductase to reduce cholesterol synthesis and upregulate LDL receptors, inhibition of the NPC1L1 transporter to reduce cholesterol absorption, inhibition of PCSK9 to increase LDL receptor density, and direct inhibition of ApoB synthesis or lipoprotein assembly.